Csl Ltd (QX) (CSLLY)

CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union

CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union PR Newswire...

CSL announces expansion of Illinois plasma therapy manufacturing facility

CSL announces expansion of Illinois plasma therapy manufacturing facility PR Newswire KING OF PRUSSIA, Pa...

Form EFFECT - Notice of Effectiveness

Form F-6 - Registration of American Depository Receipt shares, not immediately effective

Form 3 - Initial statement of beneficial ownership of securities

Securities Registration (ads, Immediate) (f-6ef)

    As filed with the Securities and Exchange Commission on June 17, 2022 Registration No. 333-_____...

CSL Behring Announces the 2015 Interlaken Leadership Awards Recipient

CSL Behring Announces the 2015 Interlaken Leadership Awards Recipient Awards Program Supports Novel Research of Immunoglobulin Therapy for...

CSL Behring Presents rIX-FP for Hemophilia B Phase III Data Evaluating Efficacy, Safety and Improved Dosing at ISTH 2015

CSL Behring Presents rIX-FP for Hemophilia B Phase III Data Evaluating Efficacy, Safety and Improved Dosing at ISTH 2015 PR Newswire TORONTO...

CSL Behring Announces Pivotal Data of Novel rVIII-SingleChain Therapy in Adolescents and Adults with Hemophilia A

CSL Behring Announces Pivotal Data of Novel rVIII-SingleChain Therapy in Adolescents and Adults with Hemophilia A PR Newswire TORONTO, June 24...

Defining And Differentiating The Value Of Therapies Used To Treat Rare Disease Patients Is A Challenge For Payers

Defining And Differentiating The Value Of Therapies Used To Treat Rare Disease Patients Is A Challenge For Payers Panel of experts examines how...

CSL Behring to Present Pivotal Data for rVIII-SingleChain and rIX-FP at 2015 ISTH Congress

CSL Behring to Present Pivotal Data for rVIII-SingleChain and rIX-FP at 2015 ISTH Congress PR Newswire KING OF PRUSSIA, Pa., June 16, 2015 More...

Important New Findings Published in The Lancet Support the Use of Zemaira® [Alpha1-Proteinase Inhibitor (Human)] in Patients...

Important New Findings Published in The Lancet Support the Use of Zemaira® [Alpha1-Proteinase Inhibitor (Human)] in Patients with Alpha-1...

National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award

National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award CSL Behring Recognized for its Longstanding Commitment to...

Science, Information, And Technology Driving Evolution Of Global Healthcare

Science, Information, And Technology Driving Evolution Of Global Healthcare Industry serves critical role in advancing healthcare and improving...